Hemogenyx Pharmaceuticals Plc (HOPHF)
USD 1.24
(0.0%)
USD 1.24
(0.0%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -6.46 Million GBP | -261.75% |
| 2022 | 3.99 Million GBP | 247.91% |
| 2021 | -2.7 Million GBP | -25.69% |
| 2020 | -2.15 Million GBP | -27.69% |
| 2019 | -1.68 Million GBP | -4.27% |
| 2018 | -1.61 Million GBP | -96.75% |
| 2017 | -820.97 Thousand GBP | -57.91% |
| 2016 | -519.89 Thousand GBP | -206.08% |
| 2015 | -169.85 Thousand GBP | -2609.04% |
| 2014 | -6270.00 GBP | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -1345.57 GBP | 0.0% |
| 2024 Q1 | -1345.57 GBP | -19.63% |
| 2023 Q3 | -671.17 GBP | 99.98% |
| 2023 FY | -5.55 Million GBP | -239.05% |
| 2023 Q4 | -1124.81 GBP | -67.59% |
| 2023 Q2 | -4.21 Million GBP | -199900.09% |
| 2023 Q1 | -2108.11 GBP | 99.93% |
| 2022 Q1 | -571.62 GBP | 99.96% |
| 2022 FY | 3.99 Million GBP | 247.91% |
| 2022 Q3 | -2193.62 GBP | 99.81% |
| 2022 Q4 | -2.85 Million GBP | -130018.13% |
| 2022 Q2 | -1.14 Million GBP | -199899.3% |
| 2021 Q1 | -580.75 GBP | 99.95% |
| 2021 FY | -2.7 Million GBP | -25.69% |
| 2021 Q4 | -1.54 Million GBP | -199900.52% |
| 2021 Q3 | -770.63 GBP | 99.93% |
| 2021 Q2 | -1.16 Million GBP | -199900.34% |
| 2020 Q3 | -620.39 GBP | 99.93% |
| 2020 Q2 | -909.6 Thousand GBP | -199900.0% |
| 2020 Q4 | -1.24 Million GBP | -199900.64% |
| 2020 Q1 | -454.80 GBP | 99.95% |
| 2020 FY | -2.15 Million GBP | -27.69% |
| 2019 FY | -1.68 Million GBP | -4.27% |
| 2019 Q4 | -896.98 Thousand GBP | -199899.55% |
| 2019 Q3 | -448.49 GBP | 99.94% |
| 2019 Q2 | -787.15 Thousand GBP | -199899.49% |
| 2019 Q1 | -393.58 GBP | 16.42% |
| 2018 Q3 | -470.90 GBP | -27.23% |
| 2018 Q2 | -370.11 GBP | 0.0% |
| 2018 Q4 | -470.90 GBP | 0.0% |
| 2018 Q1 | -370.11 GBP | -16.25% |
| 2018 FY | -1.61 Million GBP | -96.75% |
| 2017 Q4 | -318.36 GBP | 0.0% |
| 2017 FY | -820.97 Thousand GBP | -57.91% |
| 2017 Q1 | -116.98 GBP | 0.0% |
| 2017 Q3 | -318.36 GBP | -172.16% |
| 2017 Q2 | -116.98 GBP | 0.0% |
| 2016 FY | -519.89 Thousand GBP | -206.08% |
| 2015 FY | -169.85 Thousand GBP | -2609.04% |
| 2014 FY | -6270.00 GBP | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | -71.78 Million USD | 90.993% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 231.558% |
| SQZ Biotechnologies Company | -75.82 Million USD | 91.473% |
| Evofem Biosciences, Inc. | -17.84 Million USD | 63.771% |
| Santhera Pharmaceuticals Holding AG | 81.85 Million USD | 107.899% |
| Mesoblast Limited | -84.14 Million USD | 92.316% |
| Propanc Biopharma, Inc. | -1.53 Million USD | -320.94% |
| Genus plc | 6.4 Million USD | 201.029% |
| VioQuest Pharmaceuticals, Inc. | 9.74 Million USD | 166.368% |
| CNBX Pharmaceuticals Inc. | -931.38 Thousand USD | -594.222% |
| Marizyme, Inc. | -34.08 Million USD | 81.031% |
| ContraFect Corporation | -56.88 Million USD | 88.634% |
| Nymox Pharmaceutical Corporation | -8.35 Million USD | 22.565% |
| PsyBio Therapeutics Corp. | -4.55 Million USD | -41.959% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | -361.19% |
| Intellipharmaceutics International Inc. | -2.85 Million USD | -126.831% |
| AXIM Biotechnologies, Inc. | -2.75 Million USD | -135.05% |
| MultiCell Technologies, Inc. | -722.81 USD | -894442.964% |
| Accustem Sciences Inc. | -3.74 Million USD | -72.587% |
| RVL Pharmaceuticals plc | -58.99 Million USD | 89.039% |
| EV Biologics, Inc. | -483.06 Thousand USD | -1238.513% |
| Q BioMed Inc. | -3.44 Million USD | -87.654% |
| Emmaus Life Sciences, Inc. | 3.54 Million USD | 282.651% |
| Neon Bloom, Inc. | -389.57 Thousand USD | -1559.739% |
| Mosaic ImmunoEngineering Inc. | -2.62 Million USD | -146.082% |
| Biomind Labs Inc. | -1 Million USD | -540.435% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Pharming Group N.V. | -4.87 Million USD | -32.509% |
| Oncotelic Therapeutics, Inc. | -6.64 Million USD | 2.74% |
| Skye Bioscience, Inc. | -13.67 Million USD | 52.707% |
| Therapeutic Solutions International, Inc. | -1.98 Million USD | -225.493% |
| THC Farmaceuticals, Inc. | -29.95 Thousand USD | -21487.36% |
| Arch Therapeutics, Inc. | -5.04 Million USD | -28.177% |
| IMV Inc. | -38.67 Million USD | 83.28% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 59.257% |
| Curative Biotechnology, Inc. | -1.93 Million USD | -234.565% |
| GB Sciences, Inc. | -1.42 Million USD | -355.178% |
| Alpha Cognition Inc. | -9.7 Million USD | 33.38% |
| HST Global, Inc. | -140.9 Thousand USD | -4488.733% |
| CSL Limited | 3.7 Billion USD | 100.175% |
| Halberd Corporation | -75.05 Thousand USD | -8515.384% |
| Enzolytics Inc. | -2.14 Million USD | -200.905% |
| Resverlogix Corp. | -12.74 Million USD | 49.284% |
| Affymax, Inc. | -15.04 Million USD | 57.026% |
| SYBLEU INC | -149.18 Thousand USD | -4234.258% |
| Nuo Therapeutics, Inc. | -3.16 Million USD | -104.081% |
| argenx SE | -425.04 Million USD | 98.479% |
| MetaStat, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | -55.5 Million USD | 88.352% |
| Enzon Pharmaceuticals, Inc. | -1.04 Million USD | -519.334% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| RespireRx Pharmaceuticals Inc. | -1.57 Million USD | -309.398% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -3.4 Million USD | -89.894% |
| AVAX Technologies, Inc. | 6.69 Million USD | 196.608% |
| Zenith Capital Corp. | -8.94 Million USD | 27.699% |
| Genscript Biotech Corporation | -415.79 Million USD | 98.445% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -37015.24% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.45 Million USD | -163.341% |
| WPD Pharmaceuticals Inc. | -171.5 Thousand USD | -3669.963% |
| American Oriental Bioengineering, Inc. | -54.97 Million USD | 88.238% |
| Provectus Biopharmaceuticals, Inc. | -2.9 Million USD | -122.864% |
| Adynxx, Inc. | - USD | Infinity% |
| Helix BioMedix, Inc. | -984.05 Thousand USD | -557.063% |
| GlobeStar Therapeutics Corporation | -1.86 Million USD | -246.811% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -1.25 Million USD | -414.797% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | -222.525% |
| BioStem Technologies, Inc. | -7.77 Million USD | 16.88% |
| ONE Bio Corp. | 13.68 Million USD | 147.26% |
| Reve Technologies, Inc. | -181.48 Thousand USD | -3462.744% |
| Burzynski Research Institute, Inc. | -1.33 Million USD | -384.177% |
| Wesana Health Holdings Inc. | -1.12 Million USD | -474.79% |
| Agentix Corp. | -1.37 Million USD | -371.355% |
| LadRx Corporation | -3.82 Million USD | -69.102% |
| Cell Source, Inc. | -4.32 Million USD | -49.487% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -1456.239% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -841.24% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -841.24% |
| NovAccess Global Inc. | -2.46 Million USD | -162.119% |
| Endonovo Therapeutics, Inc. | -2.91 Million USD | -121.475% |
| Itoco Inc. | -919.14 Thousand USD | -603.467% |
| Rasna Therapeutics, Inc. | -4.23 Million USD | -52.553% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -477.824% |
| Kadimastem Ltd | -3.04 Million USD | -112.675% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Institute of Biomedical Research Corp. | -261.72 Thousand USD | -2370.464% |
| CytoDyn Inc. | -18.05 Million USD | 64.194% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -25.17 Thousand USD | -25588.701% |
| Mobile Lads Corp. | -554.55 Thousand USD | -1065.963% |
| NanoSphere Health Sciences Inc. | -220.07 Thousand USD | -2837.979% |
| Qrons Inc. | -643.67 Thousand USD | -904.517% |
| Alseres Pharmaceuticals, Inc. | -564.72 Thousand USD | -1044.959% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | -2.22 Million USD | -189.964% |
| Rebus Holdings, Inc. | -664 Thousand USD | -873.772% |
| ImmunoCellular Therapeutics, Ltd. | -1.81 Million USD | -255.986% |
| International Stem Cell Corporation | -663 Thousand USD | -875.241% |
| Bioxytran, Inc. | -3.82 Million USD | -69.256% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -12183.142% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -20.34 Thousand USD | -31688.82% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -36.26 Million USD | 82.171% |
| Adhera Therapeutics, Inc. | -1.61 Million USD | -299.62% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -735.83 Thousand USD | -778.709% |
| Innovation Pharmaceuticals Inc. | -3.11 Million USD | -107.838% |
| Neutra Corp. | -229.48 Thousand USD | -2717.534% |
| Windtree Therapeutics, Inc. | -17.53 Million USD | 63.134% |
| PureTech Health plc | -146.19 Million USD | 95.577% |
| Coeptis Therapeutics, Inc. | -21.49 Million USD | 69.914% |
| IXICO plc | -1.43 Million USD | -349.954% |
| IntelGenx Technologies Corp. | -9.49 Million USD | 31.874% |
| Gelesis Holdings, Inc. | -121.8 Million USD | 94.692% |
| CSL Limited | 3.81 Billion USD | 100.17% |
| Cellectis S.A. | -108.85 Million USD | 94.06% |